Background Asenapine is a new second-generation antipsychotic that is understudied in borderline personality disorder (BPD). Only one study investigating the use of the drug in this indication (an open-label pilot study) has been conducted to date.
Introduction
Treatment of borderline personality disorder (BPD) is very complex, mainly due to the heterogeneity of clinical manifestations and the poor adherence of patients to therapeutic interventions. Although many drugs were investigated across studies generating promising findings, firm conclusions regarding efficacy cannot be drawn because of methodological limitations. Furthermore, clinicians are often faced with an even more challenging situation, as recommendations provided in treatment guidelines are somewhat discordant. In particular, the UK National Institute for Health and Clinical Excellence [1] guidelines suggested psychotherapeutic interventions as the treatment of choice for BPD, thereby confining the pharmacological tools to a secondary role. On the other hand, the American Psychiatric Association [2, 3] put forward a treatment approach that is based on symptom-oriented pharmacotherapy.
In the last decade, results of meta-analyses [4] and findings of systematic reviews [5, 6] have induced a noticeable shift in experts' opinions and clinical practice from the use of antidepressants to mood-stabilizers, omega-3 fatty acids, and second-generation antipsychotics in the treatment of BPD. Therapeutic effects of antipsychotic drugs were demonstrated across a wide range of symptoms. Whilst their action is primarily directed at alleviating cognitive-perceptual symptoms such as transient paranoid ideation or dissociative symptoms, these agents were further reported to induce significant improvements across other psychopathological domains including mood instability, anxiety, impulsiveness and aggression [7] [8] [9] .
Among novel antipsychotics olanzapine is the most extensively studied across case reports [10] , open-label studies [11, 12] and double-blind, randomized controlled trials (RCTs) of patients with a diagnosis of BPD [13] [14] [15] [16] [17] [18] [19] [20] [21] . Antipsychotic drugs may owe their therapeutic efficacy to actions at D2-D4 and 5HT-2A receptors, while adverse effects are believed to be induced by antagonist activity at H1, M1-M5, and a1 receptors [22] .
To date, ten RCTs have been conducted in samples with BPD to assess the efficacy of olanzapine versus placebo [13, 16, 19, 21, 23] , versus active drugs [14, 17, 20] , or versus placebo in a combined treatment with psychotherapy (dialectical behavioral therapy) [15, 18] . The majority of accumulated evidence suggests that olanzapine is efficacious in treating cognitive-perceptual symptoms (psychotic-like symptoms) and in producing significant reduction in mood instability and impulsive behavioral dyscontrol.
Asenapine is the most recent compound approved for the acute treatment of schizophrenia and mania associated with bipolar disorder. This drug is available as a sublingual tablet formulation and acts as an antagonist at serotonin, dopamine, histamine and a2-adrenergic receptors, with almost no binding affinity for muscarinic receptors [24] . A considerable number of RCTs were performed to test the efficacy of asenapine in comparison with placebo [25] [26] [27] or active drugs [28, 29] in schizophrenia. Other studies evaluated the efficacy and tolerability of this drug in treating manic or mixed episodes of bipolar disorder, either in monotherapy or in adjunction to lithium or valproate [30] [31] [32] . Only one open-label study tested the efficacy of asenapine, in 12 BPD patients [33] , and found that after 8 weeks of treatment with asenapine (5-20 mg/day), it was efficacious, not only against BPD general symptomatology, but more specifically affective instability, impulsivity and cognitive symptoms.
With regard to tolerability, novel antipsychotics present a more favorable tolerability profile over traditional neuroleptics. Indeed, the former are associated with fewer and milder extrapyramidal adverse effects, a lower risk for developing tardive dyskinesia, as well as the possibility of enhancing cognitive functions [34] .
Nevertheless, several adverse effects have been recorded for both olanzapine and asenapine, with some differences between the two drugs. In particular, the most frequent side effects that may be caused by olanzapine are somnolence, fatigue, hyperprolactinemia, increase in metabolic parameters (glucose, triglycerides, cholesterol) and significant weight gain [18, 35] . Although asenapine may also cause somnolence, glucose increase and weight gain, recent systematic reviews of data from asenapine placebo-or olanzapine-controlled clinical trials showed that asenapine was less likely than olanzapine to induce weight gain and change the levels of glucose, triglycerides and cholesterol [29, [36] [37] [38] . Among adverse effects most frequently related to asenapine are anxiety, several extra-pyramidal symptoms, in particular akathisia, and dysgeusia/oral hypoesthesia [36] .
The present RCT set out to compare the efficacy and tolerability of asenapine and olanzapine in the treatment of BPD patients, in order to elucidate the relevant efficacy and tolerability profile of asenapine across specific symptom clusters.
Methods
A sample of 51 consecutive outpatients aged between 18 and 50 years with a diagnosis of BPD based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria [39] was recruited in the study between June 2014 and February 2016. Patients attended the Centre for Personality Disorders of the Psychiatric Clinic, Department of Neuroscience, University of Turin, Italy. The psychiatric diagnosis was made by an expert clinician and confirmed with the Structured Clinical Interview for DSM-IV Axis I and II Disorders [40, 41] . Exclusion criteria were as follows: (1) a diagnosis of dementia or other cognitive disorders, schizophrenia or other psychotic disorders, or bipolar disorders; (2) a co-occurring major depressive episode and/or substance abuse; and (3) the administration of psychotropic medications and/or psychotherapy in the 2 months preceding the beginning of the study. Female patients who did not use an adequate birth control method were also excluded. Each patient participated voluntarily in the study after providing written informed consent. The study was conducted in compliance with the Declaration of Helsinki guidelines. Approval was obtained from the ethics committee of the University Hospital ''Città della Salute e della Scienza -Ospedale dell'Ordine Mauriziano'' of Turin. The trial was registered in the Australian New Zealand Clinical Trials Registry (ANZCTR) and allocated the following code: ACTRN12614000551695.
Patients were randomly assigned to two arms of treatment for 12 weeks: asenapine (dose range 5-10 mg/day) and olanzapine (dose range 5-10 mg/day). Research Randomizer (Urbaniak and Plous, Social Psychology Network Wesleyan University, Middletown, CT), a free, webbased service for randomization, was used. All drugs were titrated (for the first 5 days at the dosage of 5 mg/day and after at the dose of 10 mg/day, if the drug was well tolerated). We administered low doses of both drugs as suggested by the American Psychiatric Association guidelines [3] . Concerning previous investigations, the only study of asenapine in BPD patients [33] used a broad dosage range of 5-20 mg/day. As for olanzapine, several studies [12, 13, 17, 21] chose the same dosage range of 5-10 mg/day used in our study.
Patients were assessed at baseline and after 12 weeks with the following assessment instruments:
1. The Clinical Global Impression Scale, Severity item (CGI-S) [ [47] 7. The Modified Overt Aggression Scale (MOAS) [48] 8. The Self-Harm Inventory (SHI) [49] .
Adverse effects of the two drugs were assessed with the Dosage Record and Treatment Emergent Symptom Scale (DOTES) [50] .
The CGI is a clinician-rated instrument to conduct global assessment of illness, and it consists of three different measures: severity of illness, global improvement, and efficacy index. In this study, severity of illness was considered and measured with the 7-point scale, ranging from 1 (normal) to 7 (extremely ill).
The HAM-D is a clinician-rated scale that scores the severity of 21 depressive symptoms in the last week. Items are variably scored 0-2, 0-3 or 0-4, with a total score ranging from 0 to 64. The HAM-A is a clinician-rated scale scoring the severity of 14 symptoms of anxiety in the last week. Items are all scored 0-4, with a total score ranging from 0 to 56.
The SOFAS is a clinician-rated scale developed to measure a patient's impairment in social and occupational domains. It is independent of the severity of patients' symptoms. The scores range between 0 and 100, with higher scores indicative of better functioning.
The BPDSI is a semi-structured clinical interview assessing frequency and severity of BPD related symptoms. The interview consists of eight items scored on 10-point frequency scales (0 = never; 10 = daily), including ''abandonment,'' ''interpersonal relationships,'' ''impulsivity,'' ''parasuicidal behavior,'' ''affective instability,'' ''emptiness,'' ''outbursts of anger,'' ''dissociation/ paranoid ideation,'' and one item scored on a 4-point severity scale concerning ''identity.''
The BIS-11 is a 30-item self-report questionnaire used to measure the trait of impulsivity on a 4-point Likert scale. Higher scores for each item indicate higher levels of impulsivity. Twelve items are reverse scored, in order to avoid response sets.
The MOAS is a clinician-rated scale consisting of four subscales for different types of aggression (verbal aggression, aggression against objects, aggression against others, and self-aggression). The subscales are rated on a 5-point scale (score 0-4) [48] .
The SHI is a brief, self-report instrument that provides data on clinically relevant self-harm behaviors. The scoring of the instrument is easily determined by counting the number of endorsed self-harm behaviors.
The DOTES is a rating scale to measure the presence and intensity of side effects induced by psychotropic medications. It consists of a broad range of 41 parameters including items on posture and movement, alertness, and cardiovascular, oral, nasal, bowel, and dermatological problems.
Assessment was performed by an investigator (P.B.) who had received a training session on psychometric instruments prior to the study.
Statistical analysis was performed both in the group of patients who completed the trial and in the whole group of patients who were randomized, including drop-outs. In the second group, intention-to-treat (ITT) analysis was performed with the last observation carried forward (LOCF). Baseline mean scores of rating scales were compared between the two treatment groups with one-way analysis of variance (ANOVA). Comparison of score change at the end of the trial between the two groups was calculated for each rating scale with ANOVA repeated measures. Bonferroni correction was applied to correct for multiple comparisons. Effect size was calculated as eta squared (g 2 ). The software system SPSS 22.0 (IBM Corporation, 2013) was used for calculations. P values were considered significant at B0.05.
Results
Fifty-one patients were randomly assigned to asenapine (N = 25) or to olanzapine (N = 26). Forty out of the 51 patients (78%) completed 12 weeks of the trial: 19 patients (47.5% of the completers) received asenapine, while 21 patients (52.5%) received olanzapine. Eleven patients (21.57%) discontinued the treatment at the fourth week: six taking asenapine and five receiving olanzapine. The final sample resulted in 40 patients with a mean age of 24.7 ± 5.3 years; there were 15 males (37.5%) and 25 females (62.5%).
Results of the ANOVA calculated for baseline mean scores of rating scales are reported in Tables 1 and 2 . No significant differences between groups were found at baseline between the two treatment arms.
The ITT-LOCF analysis was performed on the entire sample of 51 patients recruited. Results of the ANOVA repeated measures of the effects of trial duration (withinsubjects effect) and treatment modality (between-subjects effect) on the score changes after 12 weeks are reported in Tables 3, 4 , and 5.
We found a significant within-subjects effect (trial duration) for all rating scales (P ranged from 0.001 to 0.012; g 2 ranged from 0.53 to 0.25), except for the HAM-D (P = 0.862; g 2 = 0.01), the MOAS (P = 0.119; g 2 = 0.1) and two items of the BPDSI, namely, ''identity disturbance'' (P = 0.541; g 2 = 0.02) and ''parasuicidal behaviors'' (P = 0.092; g 2 = 0.14). Furthermore, a significant effect between subjects (treatment modality) was found for two items of the BPDSI: ''affective instability'' (P = 0.001, g 2 = 0.53) and ''dissociation/paranoid ideation'' (P = 0.021; g 2 = 0.21). In particular, asenapine was found superior to olanzapine in reducing the affective instability score, whereas olanzapine was found superior to asenapine in reducing dissociation/paranoid ideation.
We performed a post hoc power calculation using the software tool ClinCalc.com (ClinCalc LLC, 2017). As the main objective of our study was to detect the differences between the drugs concerning specific symptom clusters, we applied the post hoc power calculation to the two BPDSI items with a significant difference between groups: ''affective instability'' and ''dissociation/paranoid ideation.'' We ANOVA analysis of variance, BIS-11 Barratt Impulsiveness Scale, version 11, CGI-S Clinical Global Impression Scale, Severity item, HAM-A Hamilton Anxiety Rating Scale, HAM-D Hamilton Depression Rating Scale, MOAS Modified Overt Aggression Scale, SD standard deviation, SHI Self-Harm Inventory, SOFAS Social Occupational Functioning Assessment Scale obtained a power of 100% for ''affective instability,'' but power of only 39% for ''dissociation/paranoid ideation.'' These results demonstrated that the study was underpowered to detect a difference between the drugs on the ''dissociation/paranoid ideation'' item of the BPDSI.
Results of the analysis performed on the sample of 40 completers are reported in Tables 6, 7 , and 8. The significant effects found in the group of completers were not different from those found in the entire sample of 51 patients recruited. In particular, a significant effect within subjects (trial duration) was confirmed for all rating scales (P ranged from 0.001 to 0.013; g 2 ranged from 0.53 to 0.24), except from the HAM-D (P = 0.775; g 2 = 0.01), the MOAS (P = 0.119; g 2 = 0.1), and the two items of the BPDSI ''identity disturbance'' (P = 0.437; g 2 = 0.02) and ''parasuicidal behaviors'' (P = 0.086; g 2 = 0.14). The significant effect between subjects (treatment modality) was confirmed for the two items of the BPDSI ''affective instability'' (P = 0.001; g 2 = 0.53) and ''dissociation/paranoid ideation'' (P = 0.012; g 2 = 0.25). Out of the 11 subjects who discontinued treatment, four (two taking asenapine and two taking olanzapine) dropped out because of adverse effects. Specifically, two patients who received asenapine stopped the drug, one because of oral hypoesthesia and the other because of moderate anxiety. Two patients receiving olanzapine discontinued the treatment after experiencing a significant weight gain (C3 kg). The remaining seven drop-outs resulted from a lack of compliance with the trial prescription. The overall side effects reported in the two treatment arms were mild to moderate. In the asenapine treatment arm, two patients experienced akathisia and another two restlessness/anxiety, while in the olanzapine group, somnolence was observed in three patients and fatigue in two. 
Discussion
The present randomized controlled study tested the efficacy and tolerability of asenapine in comparison with olanzapine in patients affected by BPD. The aim was to investigate whether the two drugs had different effects on specific symptom clusters and profiles of tolerability. As no prior efficacy trials of asenapine versus olanzapine in BPD are available in the literature, our findings are interpreted in the light of results from head-to-head comparisons of these two drugs in schizophrenia and in bipolar disorder, as well as studies testing the efficacy of asenapine and olanzapine separately in BPD samples.
In our trial we found that the overall efficacy of asenapine was not different from olanzapine regarding global symptoms assessed with the CGI-S score, anxiety measured with the HAM-A score, and social and occupational functioning assessed with the SOFAS score. Our finding of no difference in the efficacy of asenapine and olanzapine in improving global symptomatology is consistent with reports of a meta-analysis [51] of data collected from patients with schizophrenia, and with results from clinical trials [30] of patients affected by bipolar disorder. More specifically, Szegedi et al. [51] concluded that in acute schizophrenia, the reduction of global symptomatology, as measured with the Positive and Negative Symptoms Scale ANOVA analysis of variance, BIS-11 Barratt Impulsiveness Scale, version 11, MOAS Modified Overt Aggression Scale, SD standard deviation, SHI Self-Harm Inventory, g 2 eta squared (PANSS), did not reach a statistically significant difference between treatments with asenapine and olanzapine. Moreover, a double-blind trial of patients with bipolar disorder showed non-inferiority of asenapine relative to olanzapine in extended treatment of bipolar patients during a manic episode [30] . Furthermore, we observed that neither asenapine nor olanzapine led to a significant decrease of depressive symptoms in our sample. This result is substantially in accordance with preliminary evidence provided by Buchanan et al. [28] , who found only a minimal effect of both asenapine and olanzapine on depressive symptoms in schizophrenic patients. In addition, this lack of positive effect of asenapine on depressive symptoms in BPD has already been demonstrated in an open-label study published by MartinBlanco et al. [33] . These trends are inconsistent with results of two clinical trials of subjects with bipolar disorder [52] , where asenapine was found superior to olanzapine in improving depressive symptoms during manic or mixed episodes. A possible reason for this inconsistency may be that whilst in our sample HAM-D scores at baseline were rather low (with a mean lower than 13) as patients with concomitant major depression had been excluded, in the other two studies of bipolar disorder patients [52] , depressive symptoms were rated as ''clinically relevant. '' In our study we found that neither drug significantly improved aggressive symptoms. This finding did not confirm previous data obtained by Amon et al. [53] in a group of inpatients with aggressiveness measured with the MOAS. In that study, the authors showed a significant reduction of physical aggressiveness in the group that received asenapine versus usual management. The discrepancy with our results may be due to a number of factors. The baseline MOAS total score [mean ± standard deviation (SD) = 19 ± 9.80] in patients enrolled by Amon et al. was significantly higher than the baseline MOAS score (mean ± SD = 5.50 ± 2.59) registered in our sample. Moreover, patients enrolled by Amon et al. [53] were not BPD patients, but inpatients with schizophrenia and bipolar disorders. In the only previous investigation performed by Martin-Blanco et al. [33] with asenapine in BPD subjects, the symptom of aggressiveness was not considered. Therefore, we cannot compare with other investigations our finding of the lack of effect of asenapine on aggressive symptoms. Concerning the effects of olanzapine on aggression in BPD, there is not an overall agreement among the authors who conducted previous studies. Cochrane systematic reviews on pharmacological treatment for BPD [5, 6] concluded that olanzapine induced significant decreases in affective instability, anxiety, anger, and psychotic paranoid symptoms. Aggressiveness was not listed among these effects.
With regard to the role of asenapine and olanzapine in treating specific BPD symptoms, we found that the two antipsychotics produced non-different effects on BPD-related psychopathology, impulsivity and self-injury, measured with the BPDSI total score, the BIS-11 score and the BPDSI item ''impulsivity'' score, and the SHI score, respectively.
On the other hand, significant differences of effect between the two drugs were found on measures of two core BPD symptom domains, namely, affective instability and cognitive-perceptual symptoms measured with BPDSI specific items. More specifically, asenapine was found significantly superior to olanzapine in reducing the severity of affective instability. This finding supports the evidence provided by Martin-Blanco et al. [33] of a significant effect of asenapine on affect dysregulation in BPD patients.
Furthermore, we found that olanzapine was more efficacious than asenapine against cognitive-perceptual symptoms. It must be acknowledged that this finding has a limited value, as our study was found to be underpowered to detect a difference between the drugs on the dissociation/paranoid ideation item of the BPDSI. However, the effect of olanzapine on this symptom domain in BPD patients has been widely reported in previous open-label and controlled studies. Thus, Schultz et al. [12] demonstrated a significant reduction of psychoticism in BPD patients treated with olanzapine. Moreover, Zanarini and Frankenburg [19] reported a significant improvement of paranoid ideation in BPD subjects treated with olanzapine versus placebo. More recently, this trend was confirmed in a study involving a larger BPD sample by the same research group [21] , which specified that the improvement in cognitive-perceptual symptoms (paranoid ideation and dissociation) was observed in BPD patients treated with a moderate dosage of olanzapine, ranging from 5 to 10 mg/day. Noteworthy, the dosage used in our study is within this range.
Different conclusions on this topic were drawn by Jariani et al. [14] , who compared olanzapine with sertraline in BPD subjects and did not find any significant differences between the two medications on these types of symptoms. However, in this study, the diagnosis of BPD was not supported by any standardized assessment instrument, and the effects of olanzapine and sertraline were measured in a group of heroin-dependent patients on methadone maintenance therapy.
With regard to tolerability, both treatment modalities were rather well tolerated, with only mild to moderate adverse effects reported in our sample. Nevertheless, some differences between asenapine and olanzapine were identified, with mild akathisia and restlessness/anxiety more commonly reported by patients receiving asenapine. Moreover, only two drop-outs among subjects treated with asenapine were due to adverse effects: one patient experienced oral hypoesthesia, and one moderate anxiety.
Olanzapine instead was responsible for mild somnolence and fatigue reported in our BPD patients. Two patients treated with olanzapine discontinued the drug because of a significant weight gain (C3 kg).
Our finding of several detectable differences in adverse effects between asenapine and olanzapine is consistent overall with data published in previous studies. Typically, asenapine was associated with a lower incidence of weight gain than olanzapine, more common extrapyramidal symptoms (akathisia) and oral hypoesthesia [29, [36] [37] [38] .
Study Limitations
The open-label design, the lack of a placebo group, and a rather small sample size constitute major limitations of this trial. A further possible limitation is the exclusion of subjects with co-occurring major depression, substance abuse or dependence in order to avoid their confounding effect on the outcome of the study. Given that these are common psychiatric comorbidities, the study sample may present clinical features that are partially different from those typically found in clinical practice, thereby compromising generalizability of our findings to the target population. Another limit is that we used the individual items of the BPDSI as outcome measures of several BPD symptom domains, in particular of affective instability and paranoid ideation. More specific instruments would provide more reliable results and are needed to replicate our findings. A further limitation is that data on pharmacotherapies and psychotherapies received by our patients prior to entering the study had not been collected and compared between the two treatment arms. This, however, was partially corrected by excluding patients who had received pharmacological and psychotherapeutic interventions in the 2 months before enrollment in the study. Another limitation of the study is that it was not powered to detect a difference between the drugs on the dissociation/paranoid ideation item of the BPDSI. It should be noticed that obtaining large enough samples for trials of BPD has historically proven difficult.
We had a rather high drop-out rate in our study (21.7%) , but this appears to be a common trend across the majority of preceding trials involving BPD patients, who are prone to poor adherence. However, ITT analysis with LOCF was performed to analyze data in the whole group of patients who entered the trial, and the significant effects of the two drugs found with the ANOVA were the same obtained in the group of completers.
Conclusions
In conclusion, our findings indicated that asenapine was not different from olanzapine with regard to overall measures of efficacy and general level of tolerability. Effect size, eta squared, calculated for the effect within subjects (treatment duration) ranged from 0.25 to 0.53. These are high values of size effect indicating a high level of efficacy for both medications. Moreover, some differences in therapeutic effect on specific symptom clusters were identified. Also, the types of adverse effects were partially different between the two drugs. The open-label study design, lack of a placebo group, and small sample size constitute major limitations of this trial. Another limitation is that the study was not powered to detect a difference between the drugs on the dissociation/paranoid ideation item of the BPDSI. Research in this field has major clinical implications, contributing to identify which antipsychotic is more useful to treat specific symptom domains in BPD patients. Further investigations are required to replicate our findings in larger samples.
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